GET DAILY SIGNALSThermo Fisher Scientific (TMO) Posts +9% Revenue Growth in Q3 2026 Earnings Beat
Key Takeaways
- Third quarter 2026 adjusted EPS (earnings per share) reached $6.68, above the $6.40 consensus estimate.
- Revenue rose to $12.14 billion, up 9% year over year (6% organic growth), topping the roughly $11.95 billion consensus.
- Adjusted operating income climbed 15% to $2.97 billion, and adjusted operating margin expanded to 24.5% from 23.3% a year earlier.
- Laboratory Products and Biopharma Services led the way with 15% growth, while Specialty Diagnostics revenue declined 6.5%.
- Management raised full-year 2026 guidance for both revenue and adjusted EPS, citing broad end-market strength and a one-time tariff refund benefit.
Earnings Context and Why It Matters
Thermo Fisher Scientific (TMO), the world's largest life sciences tools and services provider, serves pharmaceutical, biotech, diagnostics, and research customers worldwide. Because its results span laboratory consumables, analytical instruments, clinical diagnostics, and contract pharma services, its quarterly report is closely watched as a read on global health-care and biopharma spending. The company has now beaten earnings estimates for four consecutive quarters, and investors use this report to gauge whether demand momentum from earlier in 2026 is continuing. The third quarter also tested how well recent acquisitions, including Clario, are integrating and whether margin expansion is sustainable beyond one-time items. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Thermo Fisher Scientific (TMO) delivered third quarter 2026 adjusted EPS of $6.68, exceeding the consensus estimate of $6.40. Revenue came in at $12.14 billion, ahead of the roughly $11.95 billion expected and up 9% year over year, including 6% organic growth. Adjusted operating income rose 15% to $2.97 billion, and the adjusted operating margin expanded 120 basis points to 24.5%, above the 24% analysts had modeled.
Results were mixed by segment. Laboratory Products and Biopharma Services generated $6.86 billion in revenue, up 15% and above forecasts. Analytical Instruments revenue rose 5.8% to $2.00 billion, while Life Sciences Solutions grew 5.1% to $2.72 billion, slightly below expectations. Specialty Diagnostics declined 6.5% to $1.10 billion, also below consensus.
Management also raised full-year 2026 guidance. Revenue is now expected in a range of $47.7 billion to $48.2 billion, representing 7% to 8% reported growth, while adjusted EPS guidance was lifted to $25.13 to $25.43, implying 10% to 11% growth over 2025. Notably, about $0.15 of the quarterly EPS beat stemmed from one-time tariff refunds recovered during the period, which management said was not included in prior guidance.
Market Reaction and Investor Sentiment
Heading into the report, life sciences tools and services stocks had traded relatively flat over the prior month, with investors awaiting confirmation that demand strength seen earlier in 2026 was persisting. The third quarter beat on both revenue and EPS, coupled with a second consecutive full-year guidance raise, was broadly viewed as a sign that end-market conditions remain constructive, particularly in bioproduction and pharma services. Investors also took note of the meaningful margin expansion, though some analysts flagged that the tariff refunds inflated the quarterly figure on a one-time basis. The softer results in Specialty Diagnostics tempered enthusiasm, reminding the market that not all segments are growing at the same pace.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on whether Thermo Fisher Scientific (TMO) can sustain organic growth and margin gains without the benefit of one-time items. Management pointed to continued strength in customer activity and improving end markets, but the roughly $0.15 per share of tariff-related benefit in the third quarter will not repeat, so fourth quarter comparisons will be watched closely.
Acquisition integration remains a key theme. The Clario acquisition, which strengthens Thermo Fisher's clinical development offering, is performing well, and management expects meaningful revenue synergies over time. The filtration and separation business, which recently marked its one-year anniversary, continues to bolster bioproduction capabilities. The company also completed the divestiture of its microbiology business during the quarter, a reminder that portfolio shaping remains part of its capital deployment strategy.
Other factors to monitor include foreign exchange effects, which provided a modest tailwind in the quarter, and the pace of margin expansion driven by the company's productivity programs and its growing use of AI. Demand signals from pharmaceutical and biotech customers, along with trends in diagnostic testing volumes, will also shape whether the raised full-year guidance proves conservative. Investors should watch for further commentary on capital deployment, including potential M&A and share repurchases.
Using Tickeron’s AI Screener in My Analysis
I’ve found Tickeron’s AI Screener to be a practical addition to my routine when reviewing earnings like these. The tool lets me quickly filter life sciences names by fundamentals, growth trends, and technical signals, helping confirm how Thermo Fisher Scientific (TMO) stacks up against peers without spending hours on manual work. It’s become one of the first places I turn for context on sector momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 62 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TMO just turned positive on October 16, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 194 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 143 of 246 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 22 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.871) is normal, around the industry mean (64.450). P/E Ratio (37.293) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of analytical and environment monitoring instruments
Industry MedicalSpecialties
Advertisement